Download Files:
TAK-418
$700 – $2,250
Products Details
Product Description
– TAK-418 is a selective, orally active LSD1 (KDM1A) enzyme inhibitor with an IC50 of 2.9 nM. TAK-418 unlocks aberrant epigenetic machinery and improves autism symptoms in neurodevelopmental disorder models[1][2].
Web ID
– HY-138830
Storage Temperature
– -20°C (Powder, sealed storage, away from moisture and light)
Shipping
– Blue Ice
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C17H25ClN2O2S
References
– [1]Baba R, et al. LSD1 enzyme inhibitor TAK-418 unlocks aberrant epigenetic machinery and improves autism symptoms in neurodevelopmental disorder models. Sci Adv. 2021;7(11):eaba1187. Published 2021 Mar 12.|[2]Zhang L, et al. Inhibition of KDM1A activity restores adult neurogenesis and improves hippocampal memory in a mouse model of Kabuki syndrome. Mol Ther Methods Clin Dev. 2021;20:779-791. Published 2021 Feb 18
CAS Number
– 1818252-53-7
Molecular Weight
– 356.91
Compound Purity
– 98.64
SMILES
– O=C(C1=CSC([C@H]2[C@H](NCC3CC3)C2)=C1)NC4CCOCC4.[H]Cl
Clinical Information
– Phase 1
Research Area
– Neurological Disease
Solubility
– DMSO : 55 mg/mL (ultrasonic;warming;heat to 60°C)|H2O : ≥ 16.67 mg/mL
Target
– Histone Demethylase
Isoform
– KDM1/LSD1
Pathway
– Epigenetics
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
